EMEA: Overview of comments received on the draft guideline on the development of New Medicinal Products for the Treatment of Smoking

SRNT Europe, representing European scientists in the field of nicotine and tobacco research, is concerned that this guideline in its present form will be a barrier to the development of new effective medications for smoking cessation. Smoking is a main health burden, causing about 5 millions premature death worldwide each year. Guidelines should facilitate the emergence of new treatments in as little time as possible.